Rheumatology – Page 4

Comparative Efficacy and Safety of Tolebrutinib in Multiple Sclerosis: Insights from Recent Phase 3 Trials

By MedXY 08/02/2025

Tolebrutinib reduced disability progression in nonrelapsing secondary progressive MS but did not surpass teriflunomide in reducing relapse rates in relapsing MS. Safety signals include elevated liver enzymes and minor bleeding risks.

Clinical Updates news Rheumatology Specialties

Upadacitinib and Janus Kinase Inhibitors in Giant-Cell Arteritis: Clinical Trial and Real-World Evidence

By MedXY 08/02/2025

Upadacitinib at 15 mg with a 26-week glucocorticoid taper shows superior efficacy and comparable safety to placebo in giant-cell arteritis. Real-world data suggest JAK inhibitors, including upadacitinib, may benefit relapsing cases unresponsive to conventional therapies.

$FDA Approves First Vagus Nerve Stimulation Device for Rheumatoid Arthritis: New Horizons for Refractory Disease$

Clinical Updates news Rheumatology Specialties

FDA Approves First Vagus Nerve Stimulation Device for Rheumatoid Arthritis: New Horizons for Refractory Disease

By MedXY 07/31/2025

The FDA has approved the first vagus nerve stimulation device for moderate-to-severe rheumatoid arthritis unresponsive to biologic or synthetic DMARDs, offering a novel neuromodulatory approach to disease management.

Clinical Updates news Rheumatology Specialties

Polymyalgia Rheumatica Not Associated with Increased Mortality: Insights from a 38-Year Norwegian Cohort Study

By MedXY 07/31/2025

A 38-year prospective study in Southern Norway demonstrates that isolated polymyalgia rheumatica (PMR) does not increase all-cause mortality compared to matched population controls, with men showing even lower mortality risk.

Clinical Updates news Rheumatology Specialties

Rituximab Shows No Superiority Over Conventional Therapy for EGPA Remission Induction

By MedXY 07/31/2025

A phase 3 randomized trial found rituximab no more effective than standard glucocorticoid-based therapy in inducing remission in eosinophilic granulomatosis with polyangiitis (EGPA), with comparable safety and relapse profiles.

Clinical Updates news Rheumatology Specialties

Low Lupus Activity as a Predictive Target in Lupus Nephritis: A Clinical Appraisal of LLDAS

By MedXY 07/30/2025

Achieving low lupus disease activity (LLDAS) at 12 months is an attainable target in lupus nephritis and independently predicts reduced relapse risk and preserved renal function, supporting its potential as a future treatment goal.

Medical News Rheumatology Specialties

Johns Hopkins Hospital Leads U.S. News Rheumatology Rankings

By Dr.Paul 07/30/2025

Highlight Johns Hopkins Hospital is ranked as the best hospital for rheumatology for the 8th…

Clinical Updates news Rheumatology Specialties

Personal and Household Pesticide Exposure Linked to Increased Risk of Rheumatoid Arthritis in Female Farm Spouses

By MedXY 07/30/2025

New evidence links direct and indirect exposure to specific agricultural pesticides with increased risk of incident rheumatoid arthritis among female spouses of licensed pesticide applicators.

news Rheumatology Specialties

WHO Releases Comprehensive Guidelines for Managing Sickle Cell Disease in Pregnancy

By MedXY 07/28/2025

New WHO guidelines offer evidence-based approaches to improve care for pregnant women with sickle cell disease, focusing on treatment and maternal outcomes.